Half-Matched stem cell transplant offers hope for children with blood disorders

NCT ID NCT04356469

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new type of stem cell transplant for children with severe blood disorders like sickle cell disease or aplastic anemia. The transplant uses stem cells from a parent or other half-matched family donor, which are specially processed to remove certain immune cells. The goal is to see if this approach is safe and helps the child's body accept the donor cells without serious complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TCR alpha beta T-cell and CD19 B-cell depleted stem cell graft
What this could lead to
If successful, this approach could offer a safer transplant option for children with severe blood disorders who lack a fully matched donor.
What could go wrong
This is a small Phase 2 study, so results may not apply broadly. Risks include graft failure, infection, or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE MARROW FAILURE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johns Hopkins All Children's Hospital

    RECRUITING

    St. Petersburg, Florida, 33701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.